Theravance Biopharma Inc (TBPH)
TBPH Stock Price Chart
Explore Theravance Biopharma Inc interactive price chart. Choose custom timeframes to analyze TBPH price movements and trends.
TBPH Company Profile
Discover essential business fundamentals and corporate details for Theravance Biopharma Inc (TBPH) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
16 May 2014
Employees
90.00
Website
https://www.theravance.comCEO
Rick E. Winningham
Description
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
TBPH Financial Timeline
Browse a chronological timeline of Theravance Biopharma Inc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is $0.07, while revenue estimate is $22.49m.
Earnings released on 7 May 2026
EPS came in at -$0.10 falling short of the estimated $0.03 by -443.57%, while revenue for the quarter reached $17.70m , missing expectations by -0.47%.
Earnings released on 19 Mar 2026
EPS came in at $0.06 falling short of the estimated $0.44 by -86.36%, while revenue for the quarter reached $45.89m , missing expectations by -18.90%.
Earnings released on 10 Nov 2025
EPS came in at $0.04 surpassing the estimated -$0.03 by +233.33%, while revenue for the quarter reached $19.99m , missing expectations by -53.61%.
Earnings released on 12 Aug 2025
EPS came in at -$0.08 surpassing the estimated -$0.14 by +42.86%, while revenue for the quarter reached $26.20m , beating expectations by +39.87%.
Earnings released on 8 May 2025
EPS came in at -$0.17 falling short of the estimated -$0.11 by -54.55%, while revenue for the quarter reached $15.39m , missing expectations by -4.42%.
Earnings released on 26 Feb 2025
EPS came in at -$0.05 matching the estimated -$0.05, while revenue for the quarter reached $18.75m , beating expectations by +9.72%.
Earnings released on 12 Nov 2024
EPS came in at -$0.06 surpassing the estimated -$0.10 by +40.00%, while revenue for the quarter reached $16.87m , missing expectations by -38.25%.
Earnings released on 5 Aug 2024
EPS came in at -$0.13 falling short of the estimated -$0.09 by -44.44%, while revenue for the quarter reached $14.26m , missing expectations by -7.73%.
Earnings released on 13 May 2024
EPS came in at -$0.09 surpassing the estimated -$0.19 by +52.63%, while revenue for the quarter reached $14.50m , beating expectations by +3.89%.
Earnings released on 26 Feb 2024
EPS came in at $0.03 falling short of the estimated $0.04 by -14.36%, while revenue for the quarter reached $17.57m , missing expectations by -0.65%.
Earnings released on 7 Nov 2023
EPS came in at -$0.01 surpassing the estimated -$0.10 by +90.00%, while revenue for the quarter reached $15.69m , missing expectations by -11.24%.
Earnings released on 7 Aug 2023
EPS came in at -$0.13 surpassing the estimated -$0.16 by +18.75%, while revenue for the quarter reached $13.75m , missing expectations by -10.72%.
Earnings released on 8 May 2023
EPS came in at -$0.24 surpassing the estimated -$0.27 by +11.11%, while revenue for the quarter reached $10.42m , missing expectations by -24.73%.
Earnings released on 27 Feb 2023
EPS came in at -$0.21 falling short of the estimated -$0.20 by -5.00%, while revenue for the quarter reached $14.65m , missing expectations by -4.90%.
Earnings released on 7 Nov 2022
EPS came in at -$0.21 surpassing the estimated -$0.22 by +4.55%, while revenue for the quarter reached $12.45m , beating expectations by +5.43%.
Earnings released on 4 Aug 2022
EPS came in at -$0.04 surpassing the estimated -$0.06 by +33.33%, while revenue for the quarter reached $11.05m , missing expectations by -11.56%.
Earnings released on 5 May 2022
EPS came in at -$0.24 falling short of the estimated -$0.12 by -100.00%, while revenue for the quarter reached $13.20m , missing expectations by -8.34%.
Earnings released on 23 Feb 2022
EPS came in at -$0.43 falling short of the estimated -$0.30 by -43.33%, while revenue for the quarter reached $14.95m , beating expectations by +10.81%.
Earnings released on 3 Nov 2021
EPS came in at -$0.48 surpassing the estimated -$0.60 by +20.00%, while revenue for the quarter reached $13.19m , missing expectations by -18.05%.
Earnings released on 3 Aug 2021
EPS came in at -$0.80 surpassing the estimated -$0.96 by +16.67%, while revenue for the quarter reached $12.91m , meeting expectations.
TBPH Stock Performance
Access detailed TBPH performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
